REEVHAEMA Trademark

Trademark Overview

On Friday, October 23, 2020, a trademark application was filed for REEVHAEMA with the United States Patent and Trademark Office. The USPTO has given the REEVHAEMA trademark a serial number of 90275329. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 22, 2024. This trademark is owned by Bioverativ Therapeutics Inc.. The REEVHAEMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical product for the prevention and treatment of blood disorders, pharmaceutical product for the prevention and treatment of hemophilia, pharmaceutical product for the prevention and treatment of diseases in the immunology field
reevhaema

General Information

Serial Number90275329
Word MarkREEVHAEMA
Filing DateFriday, October 23, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 27, 2021

Trademark Statements

Goods and ServicesPharmaceutical product for the prevention and treatment of blood disorders, pharmaceutical product for the prevention and treatment of hemophilia, pharmaceutical product for the prevention and treatment of diseases in the immunology field

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, December 13, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBioverativ Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451
Party NameBioverativ Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events

Event DateEvent Description
Monday, January 22, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 22, 2024ABANDONMENT - NO USE STATEMENT FILED
Friday, May 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 10, 2023SOU EXTENSION 4 GRANTED
Wednesday, May 10, 2023SOU EXTENSION 4 FILED
Wednesday, May 10, 2023SOU TEAS EXTENSION RECEIVED
Thursday, November 10, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 8, 2022SOU EXTENSION 3 GRANTED
Tuesday, November 8, 2022SOU EXTENSION 3 FILED
Tuesday, November 8, 2022SOU TEAS EXTENSION RECEIVED
Saturday, May 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 26, 2022SOU EXTENSION 2 GRANTED
Thursday, May 26, 2022SOU EXTENSION 2 FILED
Thursday, May 26, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 10, 2021ASSIGNED TO EXAMINER
Thursday, October 28, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 26, 2021SOU EXTENSION 1 GRANTED
Tuesday, October 26, 2021SOU EXTENSION 1 FILED
Tuesday, October 26, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, June 22, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 27, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 27, 2021PUBLISHED FOR OPPOSITION
Wednesday, April 7, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 24, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 24, 2021ASSIGNED TO EXAMINER
Friday, February 19, 2021PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Tuesday, February 16, 2021ASSIGNED TO LIE
Sunday, December 13, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 12, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, October 27, 2020NEW APPLICATION ENTERED

Related Keywords

reevhaema pharmaceutical prevention treatment product immunology field diseases blood disorders hemophilia